Population Pharmacokinetics of Carbamazepine in Indian Epileptic Patients

REFERENCES

• Schain RJ. Carbamaepine and cognitive functioning. Antiepileptic drug therapy in pediatrics, PL Morselli, CE Pippenger, JK Penry. Raven Press, New York 1983; 189–92
   Google Scholar
• Dreisbach M, Ballard M, Russo DC, Schain RJ. Educational intervention for children with epilepsy: a challenge for collaborative service delivery. J Special Ed 1982; 16: 111–21
   Web of Science ®Google Scholar
• Pynnonen S. Pharmacokinetics of carbamazepine in man: a review. Ther Drug Monit 1979; 1: 409–31, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10, 11-epoxide: an update. Clin Pharmacokinet 1986; 11: 177–98, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Furlanut M, Montanari G, Bonin P, Cascara GL. Carbamazepine and carbamazepine-10, 11-epoxide serum concentrations in epileptic children. J Pediatr 1985; 106: 491–5, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• McKauge L, Tyrer JH, Eadie MJ. Factors influencing simultaneous concentrations of carbamazepine and its epoxide in plasma. Ther Drug Monit 1981; 3: 63–70, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Rambeck B, May T, Juergens U. Serum concentrations of carbamazepine and its epoxide and diol metabolites in epileptic patients: the influence of dose and comedication. Ther Drug Monit 1987; 9: 298–303, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Cox S, Hayes J, Walson PD. Carbamazepine age-dose ratio relationship in children. Ther Drug Monit 1991; 13: 201–8, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Hartley R, Lucock MD, Ng PC, Forsythe I, McLain B, Bowmer CJ. Factors influencing plasma level/dose ratios of carbamazepine and its major metabolites in epileptic children. Ther Drug Monit 1990; 12: 438–44, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Liu H, Delgado MR. Influence of sex, age, weight, and carbamazepine dose on serum concentrations, concentration ratios, and level/dose ratios of carbamazepine and its metabolites. Ther Drug Monit 1994; 16: 469–76, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• El Battah A, Beglia S, Alric R. Validation of a quick modeling program generating clearance estimates at steady state for routine therapeutic drug monitoring. Ther Drug Monit 1995; 17: 348–355, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Tanigawara Y, Yano I, Kawakatsu K, Nishimura K, Yasuhara M, Hori R. Predictive performance of the Bayesian analysis: effects of blood sampling time, population parameters and pharmacostatistical model. J Pharmacokinet Biopharm 1994; 22: 59–71, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Sheiner LB, Rosenberg R, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 1977; 5: 445–479, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Karande SC, Dalvi SS, Kshirsagar NA. Shortcomings in the pharmacotherapy of epileptic children in Bombay, India. Trop Pediatr 1995; 41(4)247–9
   PubMed Web of Science ®Google Scholar
• Sheiner LB, Grasela TH. Experience with NONMEM: Analysis of routine phenytoin clinical pharmacokinetic data. Drug Metaboism Reviews 1984; 15(1–2)293–303
   PubMed Web of Science ®Google Scholar
• Nina MG, Richard CB, Yandong W, Greg C, Elson So, Peter A, John R, Sandra K, Ilo L. Population pharmacokinetics of carbamazepine in adults with epilepsy. Pharmacotherapy 1998; 18(2)273–281
   PubMed Web of Science ®Google Scholar
• Deleu D, Aarons L, Ahmed IA. Population pharmacokinetics of free carbamazepine in adult Omani epileptic patients. Eur J Clin Pharmacol 2001; 57: 243–248, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ismail R, Rahman AFA. Estimation of population pharmacokinetics for carbamazepine in Malaysian patients using the OPT® computer program. J Clin Pharm and Therapeutics 1993; 18: 55–58
   PubMed Web of Science ®Google Scholar
• Amilcar CF, Anabela MA, Fatima L, Jorge S, Francisco S, Maria MC. Predictive capacity of carbamazepine pharmacokinetic parameters in a Portuguese outpatient population. Ther Drug Monit 1999; 21: 224–230, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• David MR, Wayne DH, John P, Bruce C. Population pharmacokinetic modeling of steady state carbamazepine clearance in children, adolescents, and adults. J Pharmacokinetics and Pharmacodynamics 2001; 28(1)79–90, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kishore P, Rajnarayana K, Reddy MS, Vidyasagar JV, Ramakrishna D. Validated HPLC method for simultaneous determination of phenytoin, phenobarbitone and carbamazepine in human serum. Arzneim Forsch /Drug research 2003; 53: 763–768
   PubMed Web of Science ®Google Scholar
• Graves NM, Brundage RC, Wen Y, Cascino G, So E, Ahman P, Rarick J, Krause S, Leppik IE. Population pharmacokinetics of carbamazepine in adults with epilepsy. Pharmacotherapy 1998; 18: 273–281, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Jiao Z, Zhong MK, Shi XJ, Hu M, Zhang JH. Population pharmacokinetics of carbamazepine in Chinese epilepsy patients. Ther Drug Monit 2003; 25(3)279–286, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Morselli PL. Carbamazepine: absorption, distribution and excretion. Antiepileptic drugs3rd, RH Levy, FE Dreifuss, RH Mattson, BS Meldrum, JK Penry. Raven Press, New York 1989; 473–490
   Google Scholar
• MacKichan JJ. Carbamazepine. A textbook for the clinical application of therapeutic drug monitoring, WJ Taylor, MH Diers Caviness. Abbot laboratories, Diagnostics Division, Irving, Texas 1986; 211–24
   Google Scholar
• Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 1983; 11: 301–19, [CROSSREF]
   Google Scholar
• Whiting B, Kelman AW, Grevel J. Population pharmacokinetics: theory and clinical application. Clin Pharmacokinet 1986; 11: 387–401, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Sheiner LB, Rosenber B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 1977; 5: 445–79, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Hundt HK, Aucamp AK, Muller FO, Poigietet MA. Carbamazepine and its major metabolities in plasma: a summary of eight years of therapuetic drug monitoring. Ther Drug Monit 1983; 5: 427–435, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Rambeck B, May T, Juergens U. Serum concentrations of carbamazepine and its epoxide and diol metabolities in epileptic patients: the influence of dose and comedication. Ther Drug Monit 1987; 9: 298–303, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Hartley R, Lucock MD, Ng PC, Forsythe WI, McLain B, Browmer CJ. Factors influencing plasma level/dose ratios of carbamazepine and its metabolites in epileptic children. Ther Drug Monit 1990; 12: 438–444, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Svinarov DA, Pippenger CE. Relationships between carbamazepine-diol, carbamazepine epoxide, and carbamazepine total and free steady-state concentrations in epileptic patients: the influence of age, sex and comedication. Ther Drug Monit 1991; 18: 660–665, [CROSSREF]
   Google Scholar
• Macphee GJ, Brodie MJ. Carbamazepine substitution in severe partial epilepsy: implication of autoinduction of metabolism. Postgrad Med 1985; 61: 779–783
   Google Scholar
• Kudrikova TB, Siroto LA, Rozova GI, Gorkov VA. Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites. Br J Clin Pharmacol 1992; 33: 611–615
   PubMed Web of Science ®Google Scholar
• Nolen WA, Jansen GS, Broekman M. Measuring plasma levels of carbamazepine. A pharmacokinetic study in patients with affective disorders. Pharmacopsychiatry. 1988; 21: 252–254, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Tomson T, Svensson JO, Hilton-Brown P. Relationship of intraindividual dose to plasma concentration of carbamazepine. Indication dose-dependent induction of metabolism. Ther Drug Monit 1989; 11: 533–539, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Lanchote VL, Bonato PS, Campos GM, Rodrigues I. Factors influencing plasma concentrations of carbamazepine and carbamazepine-10, 11-epoxide in epileptic children and adults. Ther Drug Monit 1995; 17: 47–52, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Cox S, Hayes J, Walson PD. Carbamazepine age-dose ratio relationship in children. Ther Drug Monit 1991; 13: 201–8, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Summers B, Summers RS. Carbamazepine clearance in pediatric epilepsy patients: influence of body mass, dose, sex and co-medication. Clin Pharmacokinet 1989; 17: 208–16, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Altafullah I, Talwar D, Loewenson R, Olson K, Lockman LA. Factors influencing serum levels of carbamazepine-10, 11-epoxide in children. Epilepsy Res 1989; 4: 72–80, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Delen D, Aarons L, Ahmed IA. Population pharmacokinetics of free carbamazepine in adult Omani epileptic patients. Eur J Clin Pharmacol 2001; 57: 243–8, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Battino D, Estienne M, Avanzini G. Clinical Pharmacokinetics of antiepileptic drug in pediatric patients. Part II: Phenytoin, carbamazepine, sulthiame. Lamotrigine, vigabatrin, oxycarbazepine and felbamate. Clin Pharmacokinet 1995; 29: 341–69, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Benet LZ, Williams RL. Appendix II. Design and optimization of dosage regimens: Pharmacokinetic data. Goodman and Gilman's The Pharmacological basis of Therapeutics. International8th, G Gilman, TW Rall, AS Nies, AS Taylor. McGraw-Hill, Singapore 1991; 1650–1736
   Google Scholar
• Tomson T, Svensson JO, Hilton-Brown P. Relationship of intraindividual dose-plasma concentration of carbamazepine: indication of dose-dependent induction of metabolism. Ther Drug Monit 1989; 11: 533–539, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Graves DA, Locke CS, Muir KT, Miller RP. The influence of assay variability on pharmacokinetic parameter estimation. J Pharmacokin Biopharm 1989; 17: 571–592, [CROSSREF]
   PubMedGoogle Scholar
• Martin ES, Crismon ML, Godley PJ. Postinduction carbamazepine clearance in an adult psychiatric population. Pharmacotherapy 1991; 11: 296–302, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Gaulier JM, Roulieu R, Fischer C, Maugmer F. Prediction of carbamazepine concentrations using a Bayesian program (PKS system, Abbot): a retrospective evaluation in an outpatient population. J Pharm Pharmacol 1997; 49: 734–736, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar